Unknown

Dataset Information

0

Intramuscular 17-hydroxyprogesterone caproate to prevent preterm birth among HIV-infected women in Zambia: study protocol of the IPOP randomized trial.


ABSTRACT: BACKGROUND:Each year, an estimated 15 million babies are born preterm, a global burden borne disproportionately by families in lower-income countries. Maternal HIV infection increases a woman's risk of delivering prematurely, and antiretroviral therapy (ART) may compound this risk. While prenatal progesterone prophylaxis prevents preterm birth among some high-risk women, it is unknown whether HIV-infected women could benefit from this therapy. We are studying the efficacy of progesterone supplementation to reduce the risk of preterm birth among pregnant women with HIV in Lusaka, Zambia. METHODS:The Improving Pregnancy Outcomes with Progesterone (IPOP) study is a Phase III double-masked, placebo-controlled, randomized trial of intramuscular 17-alpha hydroxprogesterone caproate (17P) to prevent preterm birth in HIV-infected women. A total of 800 women will be recruited prior to 24?weeks of gestation and randomly allocated to 17P or placebo administered by weekly intramuscular injection. The primary outcome will be a composite of live birth prior to 37 completed gestational weeks or stillbirth at any gestational age. Secondary outcomes will include very preterm birth (

SUBMITTER: Price JT 

PROVIDER: S-EPMC6391830 | biostudies-literature | 2019 Feb

REPOSITORIES: biostudies-literature

altmetric image

Publications

Intramuscular 17-hydroxyprogesterone caproate to prevent preterm birth among HIV-infected women in Zambia: study protocol of the IPOP randomized trial.

Price Joan T JT   Vwalika Bellington B   Freeman Bethany L BL   Cole Stephen R SR   Mulenga Helen B HB   Winston Jennifer J   Mbewe Felistas M FM   Chomba Elwyn E   Mofenson Lynne M LM   Rouse Dwight J DJ   Goldenberg Robert L RL   Stringer Jeffrey S A JSA  

BMC pregnancy and childbirth 20190227 1


<h4>Background</h4>Each year, an estimated 15 million babies are born preterm, a global burden borne disproportionately by families in lower-income countries. Maternal HIV infection increases a woman's risk of delivering prematurely, and antiretroviral therapy (ART) may compound this risk. While prenatal progesterone prophylaxis prevents preterm birth among some high-risk women, it is unknown whether HIV-infected women could benefit from this therapy. We are studying the efficacy of progesterone  ...[more]

Similar Datasets

| S-EPMC3991237 | biostudies-literature
| S-EPMC4266558 | biostudies-literature
| S-EPMC8476342 | biostudies-literature
| S-EPMC2790283 | biostudies-literature
| S-EPMC8049867 | biostudies-literature
| S-EPMC6890226 | biostudies-literature
| S-EPMC5449222 | biostudies-literature
| S-EPMC8317597 | biostudies-literature
| S-EPMC8595047 | biostudies-literature
| S-EPMC3165062 | biostudies-literature